“As topoisomerase inhibitor–based ADCs achieve broad clinical success and move into earlier lines of therapy, a growing unmet medical need is emerging for patients whose tumors are resistant or refractory to this payload class. We built DUPAC to help address this challenge with a family of next-generation payloads designed to overcome resistance and enable each ADC program to expand the breadth of the underlying tumor biology. By combining DualityBio’s payload innovation and early-stage global clinical development capabilities with Genentech’s deep oncology expertise and worldwide development reach, we can advance these programs with greater speed and scale and bring differentiated medicines to more patients around the world,” said Dr. John Zhu, Founder and Chief Executive Officer of DualityBio.